Welcome to our dedicated page for Pharma-Bio Serv news (Ticker: PBSV), a resource for investors and traders seeking the latest updates and insights on Pharma-Bio Serv stock.
Pharma-Bio Serv reports recurring updates as an OTCQB-traded consulting firm providing regulatory affairs, quality, compliance, project management and technology-transfer support to pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries. Company announcements primarily cover quarterly and annual operating results, revenue and net income trends, service-portfolio adjustments, cost-structure discipline, client and project activity, and special cash dividends approved by the board.
Pharma-Bio Serv (OTCQB:PBSV) reported results for the quarter ended January 31, 2026: quarterly revenue of approximately $2.3 million, a year-over-year decrease of about $0.2 million, and net income of $32,860, an improvement of $24,324 versus the same period last year.
Management cited operational efficiency gains, disciplined cost management, and a focus on core markets as drivers of the modest profit and said it aims to build momentum to deliver long-term shareholder value.
Pharma-Bio Serv (OTCQB:PBSV) reported fiscal year ended October 31, 2025 revenue of approximately $9.0 million, down roughly $0.5 million versus prior year, and a net loss of approximately $0.1 million, an improvement of about $0.7 million year-over-year. The Board approved a Special Dividend of $0.075 per share, payable on or about March 20, 2026, to shareholders of record at the close of business on February 27, 2026. Management said it rationalized services and clients, realigned the organization, and is targeting selective opportunities in Latin America and high-value segments in Europe to support improved performance in 2026.
Pharma-Bio Serv (OTCQB:PBSV), a consulting firm serving pharmaceutical and related industries, reported financial results for Q3 2025. The company posted revenues of $2.0 million for the quarter and $6.9 million for the nine months ended July 31, 2025, compared to $2.4 million and $7.2 million in the respective periods of 2024.
Despite lower revenues, the company reduced its net loss to $0.2 million for Q3 and $0.1 million for the nine-month period, representing improvements of $0.1 million and $0.7 million year-over-year, respectively. Management highlighted strategic initiatives including cost structure optimization and focus on core business segments.
Pharma-Bio Serv (OTCQB:PBSV), a compliance and consulting firm serving pharmaceutical and related industries, reported financial results for Q1 2025. The company achieved revenues of $2.5 million for the quarter ended January 31, 2025, marking a $0.1 million increase compared to the same period last year.
The company reached near breakeven net income, showing significant improvement with a $0.3 million earnings increase year-over-year. The company currently has ongoing projects across Europe, Asia, and Latin America, positioning itself for continued market expansion.
Pharma-Bio Serv (OTCQB:PBSV) reported financial results for the fiscal year ended October 31, 2024. The company experienced a significant decline in performance, with revenues dropping to $9.5 million, representing a decrease of $7.5 million compared to the previous year. The company reported a net loss of $0.8 million, contrasting with a net income of $1.3 million in the prior year.
Despite challenging market conditions, particularly in new investments and projects, the company implemented strategic measures focusing on higher-value services and business development, including technology adoption. The Board of Directors approved a Special Dividend of $0.075 per share, payable around March 20, 2025, demonstrating confidence in their business plan and commitment to shareholder value.
Pharma-Bio Serv (OTCQB:PBSV), a consulting firm serving pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, has announced a special dividend of $0.075 per share. The company, which specializes in regulatory affairs, quality, compliance, project management and technology transfer support, will distribute the dividend on March 20, 2025 to shareholders of record as of February 28, 2025.
Pharma-Bio Serv (OTCQB:PBSV), a consulting firm for pharmaceutical and related industries, reported financial results for Q3 2024. The company experienced a significant decline in revenues and profitability. Revenues for the three and nine months ended July 31, 2024, were $2.4 million and $7.2 million respectively, representing decreases of $2.2 million and $6.2 million compared to the same periods last year. The company reported net losses of $0.3 million and $0.8 million for the three and nine-month periods, contrasting with net incomes of $0.5 million and $1.4 million in the previous year. CEO Mr. Sanchez acknowledged industry challenges but highlighted investments in technological tools to identify global business opportunities, aiming to restore profitability and revenue growth.
Pharma-Bio Serv (OTCQB:PBSV), a consulting firm serving various industries including pharmaceuticals, announced a revenue decline for the three and six months ending April 30, 2024. Revenues were $2.4 million and $4.8 million, respectively, marking a decrease of $2.2 million and $4.0 million compared to the same periods last year. The company reported a net loss of $0.2 million and $0.5 million for these periods, compared to net income of $0.4 million and $0.8 million in the previous year. Despite these setbacks, the company is investing in new client relationships and global events to foster growth and stability in the future.
Summary not available.